Italfarmaco Options Inhaled Teicoplanin For MRSA Lung Infections
Executive Summary
Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.
You may also be interested in...
In Hindsight, Savara Wishes It Led With Patient-Reported Secondary Endpoint For Molgradex
Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.
While You Were Out: News In Brief
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.